instruction stringlengths 34 186 | input stringlengths 2.02k 93.8k | output stringlengths 2 418 | meta_questiontype stringclasses 6
values | meta_inputlicense stringclasses 6
values | meta_pmid stringlengths 8 8 | meta_safetyreportid int64 9.51M 21M | meta_articlepubdate stringlengths 4 10 |
|---|---|---|---|---|---|---|---|
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Thrombocytopenia'. | Severe Adverse Toxic Effects of Low-Dose Methotrexate Treatment on an Ectopic Pregnancy Patient With Methylenetetrahydrofolate Reductase Mutations: A Case Report.
Background: Low-dose methylenetetrahydrofolate (LD-MTX) has been widely used for the treatment of the ectopic pregnancy (EP) for many decades, and related se... | METHOTREXATE | DrugsGivenReaction | CC BY | 34869432 | 20,215,525 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Vomiting'. | Severe Adverse Toxic Effects of Low-Dose Methotrexate Treatment on an Ectopic Pregnancy Patient With Methylenetetrahydrofolate Reductase Mutations: A Case Report.
Background: Low-dose methylenetetrahydrofolate (LD-MTX) has been widely used for the treatment of the ectopic pregnancy (EP) for many decades, and related se... | METHOTREXATE | DrugsGivenReaction | CC BY | 34869432 | 20,215,525 | 2021 |
What was the administration route of drug 'METHOTREXATE'? | Severe Adverse Toxic Effects of Low-Dose Methotrexate Treatment on an Ectopic Pregnancy Patient With Methylenetetrahydrofolate Reductase Mutations: A Case Report.
Background: Low-dose methylenetetrahydrofolate (LD-MTX) has been widely used for the treatment of the ectopic pregnancy (EP) for many decades, and related se... | Intramuscular | DrugAdministrationRoute | CC BY | 34869432 | 20,215,525 | 2021 |
What was the outcome of reaction 'Alanine aminotransferase increased'? | Severe Adverse Toxic Effects of Low-Dose Methotrexate Treatment on an Ectopic Pregnancy Patient With Methylenetetrahydrofolate Reductase Mutations: A Case Report.
Background: Low-dose methylenetetrahydrofolate (LD-MTX) has been widely used for the treatment of the ectopic pregnancy (EP) for many decades, and related se... | Recovered | ReactionOutcome | CC BY | 34869432 | 20,215,525 | 2021 |
What was the outcome of reaction 'Anal inflammation'? | Severe Adverse Toxic Effects of Low-Dose Methotrexate Treatment on an Ectopic Pregnancy Patient With Methylenetetrahydrofolate Reductase Mutations: A Case Report.
Background: Low-dose methylenetetrahydrofolate (LD-MTX) has been widely used for the treatment of the ectopic pregnancy (EP) for many decades, and related se... | Recovering | ReactionOutcome | CC BY | 34869432 | 20,215,525 | 2021 |
What was the outcome of reaction 'Back pain'? | Severe Adverse Toxic Effects of Low-Dose Methotrexate Treatment on an Ectopic Pregnancy Patient With Methylenetetrahydrofolate Reductase Mutations: A Case Report.
Background: Low-dose methylenetetrahydrofolate (LD-MTX) has been widely used for the treatment of the ectopic pregnancy (EP) for many decades, and related se... | Recovering | ReactionOutcome | CC BY | 34869432 | 20,215,525 | 2021 |
What was the outcome of reaction 'Diarrhoea'? | Severe Adverse Toxic Effects of Low-Dose Methotrexate Treatment on an Ectopic Pregnancy Patient With Methylenetetrahydrofolate Reductase Mutations: A Case Report.
Background: Low-dose methylenetetrahydrofolate (LD-MTX) has been widely used for the treatment of the ectopic pregnancy (EP) for many decades, and related se... | Recovering | ReactionOutcome | CC BY | 34869432 | 20,215,525 | 2021 |
What was the outcome of reaction 'Drug intolerance'? | Severe Adverse Toxic Effects of Low-Dose Methotrexate Treatment on an Ectopic Pregnancy Patient With Methylenetetrahydrofolate Reductase Mutations: A Case Report.
Background: Low-dose methylenetetrahydrofolate (LD-MTX) has been widely used for the treatment of the ectopic pregnancy (EP) for many decades, and related se... | Recovering | ReactionOutcome | CC BY | 34869432 | 20,215,525 | 2021 |
What was the outcome of reaction 'Drug level increased'? | Severe Adverse Toxic Effects of Low-Dose Methotrexate Treatment on an Ectopic Pregnancy Patient With Methylenetetrahydrofolate Reductase Mutations: A Case Report.
Background: Low-dose methylenetetrahydrofolate (LD-MTX) has been widely used for the treatment of the ectopic pregnancy (EP) for many decades, and related se... | Recovered | ReactionOutcome | CC BY | 34869432 | 20,215,525 | 2021 |
What was the outcome of reaction 'Ear swelling'? | Severe Adverse Toxic Effects of Low-Dose Methotrexate Treatment on an Ectopic Pregnancy Patient With Methylenetetrahydrofolate Reductase Mutations: A Case Report.
Background: Low-dose methylenetetrahydrofolate (LD-MTX) has been widely used for the treatment of the ectopic pregnancy (EP) for many decades, and related se... | Recovering | ReactionOutcome | CC BY | 34869432 | 20,215,525 | 2021 |
What was the outcome of reaction 'Haematotoxicity'? | Severe Adverse Toxic Effects of Low-Dose Methotrexate Treatment on an Ectopic Pregnancy Patient With Methylenetetrahydrofolate Reductase Mutations: A Case Report.
Background: Low-dose methylenetetrahydrofolate (LD-MTX) has been widely used for the treatment of the ectopic pregnancy (EP) for many decades, and related se... | Recovered | ReactionOutcome | CC BY | 34869432 | 20,215,525 | 2021 |
What was the outcome of reaction 'Hepatotoxicity'? | Severe Adverse Toxic Effects of Low-Dose Methotrexate Treatment on an Ectopic Pregnancy Patient With Methylenetetrahydrofolate Reductase Mutations: A Case Report.
Background: Low-dose methylenetetrahydrofolate (LD-MTX) has been widely used for the treatment of the ectopic pregnancy (EP) for many decades, and related se... | Recovered | ReactionOutcome | CC BY | 34869432 | 20,215,525 | 2021 |
What was the outcome of reaction 'Mucosal toxicity'? | Severe Adverse Toxic Effects of Low-Dose Methotrexate Treatment on an Ectopic Pregnancy Patient With Methylenetetrahydrofolate Reductase Mutations: A Case Report.
Background: Low-dose methylenetetrahydrofolate (LD-MTX) has been widely used for the treatment of the ectopic pregnancy (EP) for many decades, and related se... | Recovering | ReactionOutcome | CC BY | 34869432 | 20,215,525 | 2021 |
What was the outcome of reaction 'Myelosuppression'? | Severe Adverse Toxic Effects of Low-Dose Methotrexate Treatment on an Ectopic Pregnancy Patient With Methylenetetrahydrofolate Reductase Mutations: A Case Report.
Background: Low-dose methylenetetrahydrofolate (LD-MTX) has been widely used for the treatment of the ectopic pregnancy (EP) for many decades, and related se... | Recovered | ReactionOutcome | CC BY | 34869432 | 20,215,525 | 2021 |
What was the outcome of reaction 'Nausea'? | Severe Adverse Toxic Effects of Low-Dose Methotrexate Treatment on an Ectopic Pregnancy Patient With Methylenetetrahydrofolate Reductase Mutations: A Case Report.
Background: Low-dose methylenetetrahydrofolate (LD-MTX) has been widely used for the treatment of the ectopic pregnancy (EP) for many decades, and related se... | Recovering | ReactionOutcome | CC BY | 34869432 | 20,215,525 | 2021 |
What was the outcome of reaction 'Neutropenia'? | Severe Adverse Toxic Effects of Low-Dose Methotrexate Treatment on an Ectopic Pregnancy Patient With Methylenetetrahydrofolate Reductase Mutations: A Case Report.
Background: Low-dose methylenetetrahydrofolate (LD-MTX) has been widely used for the treatment of the ectopic pregnancy (EP) for many decades, and related se... | Recovered | ReactionOutcome | CC BY | 34869432 | 20,215,525 | 2021 |
What was the outcome of reaction 'Occult blood'? | Severe Adverse Toxic Effects of Low-Dose Methotrexate Treatment on an Ectopic Pregnancy Patient With Methylenetetrahydrofolate Reductase Mutations: A Case Report.
Background: Low-dose methylenetetrahydrofolate (LD-MTX) has been widely used for the treatment of the ectopic pregnancy (EP) for many decades, and related se... | Recovering | ReactionOutcome | CC BY | 34869432 | 20,215,525 | 2021 |
What was the outcome of reaction 'Oropharyngeal pain'? | Severe Adverse Toxic Effects of Low-Dose Methotrexate Treatment on an Ectopic Pregnancy Patient With Methylenetetrahydrofolate Reductase Mutations: A Case Report.
Background: Low-dose methylenetetrahydrofolate (LD-MTX) has been widely used for the treatment of the ectopic pregnancy (EP) for many decades, and related se... | Recovering | ReactionOutcome | CC BY | 34869432 | 20,215,525 | 2021 |
What was the outcome of reaction 'Pyrexia'? | Severe Adverse Toxic Effects of Low-Dose Methotrexate Treatment on an Ectopic Pregnancy Patient With Methylenetetrahydrofolate Reductase Mutations: A Case Report.
Background: Low-dose methylenetetrahydrofolate (LD-MTX) has been widely used for the treatment of the ectopic pregnancy (EP) for many decades, and related se... | Recovering | ReactionOutcome | CC BY | 34869432 | 20,215,525 | 2021 |
What was the outcome of reaction 'Rash maculo-papular'? | Severe Adverse Toxic Effects of Low-Dose Methotrexate Treatment on an Ectopic Pregnancy Patient With Methylenetetrahydrofolate Reductase Mutations: A Case Report.
Background: Low-dose methylenetetrahydrofolate (LD-MTX) has been widely used for the treatment of the ectopic pregnancy (EP) for many decades, and related se... | Recovering | ReactionOutcome | CC BY | 34869432 | 20,215,525 | 2021 |
What was the outcome of reaction 'Renal pain'? | Severe Adverse Toxic Effects of Low-Dose Methotrexate Treatment on an Ectopic Pregnancy Patient With Methylenetetrahydrofolate Reductase Mutations: A Case Report.
Background: Low-dose methylenetetrahydrofolate (LD-MTX) has been widely used for the treatment of the ectopic pregnancy (EP) for many decades, and related se... | Recovering | ReactionOutcome | CC BY | 34869432 | 20,215,525 | 2021 |
What was the outcome of reaction 'Stomatitis'? | Severe Adverse Toxic Effects of Low-Dose Methotrexate Treatment on an Ectopic Pregnancy Patient With Methylenetetrahydrofolate Reductase Mutations: A Case Report.
Background: Low-dose methylenetetrahydrofolate (LD-MTX) has been widely used for the treatment of the ectopic pregnancy (EP) for many decades, and related se... | Recovering | ReactionOutcome | CC BY | 34869432 | 20,215,525 | 2021 |
What was the outcome of reaction 'Thrombocytopenia'? | Severe Adverse Toxic Effects of Low-Dose Methotrexate Treatment on an Ectopic Pregnancy Patient With Methylenetetrahydrofolate Reductase Mutations: A Case Report.
Background: Low-dose methylenetetrahydrofolate (LD-MTX) has been widely used for the treatment of the ectopic pregnancy (EP) for many decades, and related se... | Recovered | ReactionOutcome | CC BY | 34869432 | 20,215,525 | 2021 |
What was the outcome of reaction 'Vomiting'? | Severe Adverse Toxic Effects of Low-Dose Methotrexate Treatment on an Ectopic Pregnancy Patient With Methylenetetrahydrofolate Reductase Mutations: A Case Report.
Background: Low-dose methylenetetrahydrofolate (LD-MTX) has been widely used for the treatment of the ectopic pregnancy (EP) for many decades, and related se... | Recovering | ReactionOutcome | CC BY | 34869432 | 20,215,525 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Atrioventricular block complete'. | A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil.
Immune checkpoint inhibitor (ICI)-related myocarditis is an uncommon but potentially fatal immune-related adverse event. Corticoid-resistant myocardit... | METHYLPREDNISOLONE | DrugsGivenReaction | CC BY-NC | 34870082 | 20,226,416 | 2021-11 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Disease progression'. | A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil.
Immune checkpoint inhibitor (ICI)-related myocarditis is an uncommon but potentially fatal immune-related adverse event. Corticoid-resistant myocardit... | METHYLPREDNISOLONE | DrugsGivenReaction | CC BY-NC | 34870082 | 20,226,416 | 2021-11 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective for unapproved indication'. | A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil.
Immune checkpoint inhibitor (ICI)-related myocarditis is an uncommon but potentially fatal immune-related adverse event. Corticoid-resistant myocardit... | ABATACEPT, IPILIMUMAB, METHYLPREDNISOLONE, MYCOPHENOLATE MOFETIL | DrugsGivenReaction | CC BY-NC | 34870082 | 20,535,403 | 2021-11 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug resistance'. | A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil.
Immune checkpoint inhibitor (ICI)-related myocarditis is an uncommon but potentially fatal immune-related adverse event. Corticoid-resistant myocardit... | METHYLPREDNISOLONE | DrugsGivenReaction | CC BY-NC | 34870082 | 20,226,416 | 2021-11 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Immune-mediated myositis'. | A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil.
Immune checkpoint inhibitor (ICI)-related myocarditis is an uncommon but potentially fatal immune-related adverse event. Corticoid-resistant myocardit... | IPILIMUMAB, NIVOLUMAB | DrugsGivenReaction | CC BY-NC | 34870082 | 20,295,830 | 2021-11 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Myasthenic syndrome'. | A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil.
Immune checkpoint inhibitor (ICI)-related myocarditis is an uncommon but potentially fatal immune-related adverse event. Corticoid-resistant myocardit... | IPILIMUMAB, NIVOLUMAB | DrugsGivenReaction | CC BY-NC | 34870082 | 20,295,830 | 2021-11 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Ventricular tachycardia'. | A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil.
Immune checkpoint inhibitor (ICI)-related myocarditis is an uncommon but potentially fatal immune-related adverse event. Corticoid-resistant myocardit... | ABATACEPT, IPILIMUMAB, METHYLPREDNISOLONE, MYCOPHENOLATE MOFETIL | DrugsGivenReaction | CC BY-NC | 34870082 | 20,535,403 | 2021-11 |
What was the administration route of drug 'ABATACEPT'? | A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil.
Immune checkpoint inhibitor (ICI)-related myocarditis is an uncommon but potentially fatal immune-related adverse event. Corticoid-resistant myocardit... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC | 34870082 | 20,535,403 | 2021-11 |
What was the administration route of drug 'METHYLPREDNISOLONE'? | A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil.
Immune checkpoint inhibitor (ICI)-related myocarditis is an uncommon but potentially fatal immune-related adverse event. Corticoid-resistant myocardit... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC | 34870082 | 20,226,416 | 2021-11 |
What was the administration route of drug 'MYCOPHENOLATE MOFETIL'? | A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil.
Immune checkpoint inhibitor (ICI)-related myocarditis is an uncommon but potentially fatal immune-related adverse event. Corticoid-resistant myocardit... | Oral | DrugAdministrationRoute | CC BY-NC | 34870082 | 20,535,403 | 2021-11 |
What was the dosage of drug 'ABATACEPT'? | A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil.
Immune checkpoint inhibitor (ICI)-related myocarditis is an uncommon but potentially fatal immune-related adverse event. Corticoid-resistant myocardit... | 500 MILLIGRAM EVERY 2 WEEKS, FOR A TOTAL OF 5 DOSES | DrugDosageText | CC BY-NC | 34870082 | 20,535,403 | 2021-11 |
What was the dosage of drug 'MYCOPHENOLATE MOFETIL'? | A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil.
Immune checkpoint inhibitor (ICI)-related myocarditis is an uncommon but potentially fatal immune-related adverse event. Corticoid-resistant myocardit... | 1 GRAM, BID FOR 3 MONTHS | DrugDosageText | CC BY-NC | 34870082 | 20,535,403 | 2021-11 |
What was the dosage of drug 'NIVOLUMAB'? | A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil.
Immune checkpoint inhibitor (ICI)-related myocarditis is an uncommon but potentially fatal immune-related adverse event. Corticoid-resistant myocardit... | 3 MILLIGRAM/KILOGRAM | DrugDosageText | CC BY-NC | 34870082 | 20,295,830 | 2021-11 |
What was the outcome of reaction 'Immune-mediated myocarditis'? | A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil.
Immune checkpoint inhibitor (ICI)-related myocarditis is an uncommon but potentially fatal immune-related adverse event. Corticoid-resistant myocardit... | Recovering | ReactionOutcome | CC BY-NC | 34870082 | 20,295,830 | 2021-11 |
What was the outcome of reaction 'Immune-mediated myositis'? | A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil.
Immune checkpoint inhibitor (ICI)-related myocarditis is an uncommon but potentially fatal immune-related adverse event. Corticoid-resistant myocardit... | Recovering | ReactionOutcome | CC BY-NC | 34870082 | 20,295,830 | 2021-11 |
What was the outcome of reaction 'Myasthenic syndrome'? | A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil.
Immune checkpoint inhibitor (ICI)-related myocarditis is an uncommon but potentially fatal immune-related adverse event. Corticoid-resistant myocardit... | Recovering | ReactionOutcome | CC BY-NC | 34870082 | 20,295,830 | 2021-11 |
What was the outcome of reaction 'Ventricular tachycardia'? | A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil.
Immune checkpoint inhibitor (ICI)-related myocarditis is an uncommon but potentially fatal immune-related adverse event. Corticoid-resistant myocardit... | Recovered | ReactionOutcome | CC BY-NC | 34870082 | 20,535,403 | 2021-11 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'COVID-19 pneumonia'. | Using 18F-FDG PET/CT to rule out Richter transformation as cause of deterioration in a patient with chronic lymphatic leukemia and severe COVID-19: A case report.
BACKGROUND
This case report demonstrates the use of flourine-18 fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) to r... | CYCLOPHOSPHAMIDE, FLUDARABINE PHOSPHATE, IBRUTINIB, IMMUNE GLOBULIN NOS, ITRACONAZOLE, RITUXIMAB, VENETOCLAX | DrugsGivenReaction | CC BY | 34871217 | 20,547,124 | 2021-11-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Malaise'. | Using 18F-FDG PET/CT to rule out Richter transformation as cause of deterioration in a patient with chronic lymphatic leukemia and severe COVID-19: A case report.
BACKGROUND
This case report demonstrates the use of flourine-18 fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) to r... | CYCLOPHOSPHAMIDE, FLUDARABINE PHOSPHATE, IBRUTINIB, IMMUNE GLOBULIN NOS, ITRACONAZOLE, RITUXIMAB, VENETOCLAX | DrugsGivenReaction | CC BY | 34871217 | 20,547,124 | 2021-11-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pyrexia'. | Using 18F-FDG PET/CT to rule out Richter transformation as cause of deterioration in a patient with chronic lymphatic leukemia and severe COVID-19: A case report.
BACKGROUND
This case report demonstrates the use of flourine-18 fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) to r... | CYCLOPHOSPHAMIDE, FLUDARABINE PHOSPHATE, IBRUTINIB, IMMUNE GLOBULIN NOS, ITRACONAZOLE, RITUXIMAB, VENETOCLAX | DrugsGivenReaction | CC BY | 34871217 | 20,547,124 | 2021-11-05 |
What was the administration route of drug 'IMMUNE GLOBULIN NOS'? | Using 18F-FDG PET/CT to rule out Richter transformation as cause of deterioration in a patient with chronic lymphatic leukemia and severe COVID-19: A case report.
BACKGROUND
This case report demonstrates the use of flourine-18 fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) to r... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 34871217 | 20,547,124 | 2021-11-05 |
What was the dosage of drug 'CYCLOPHOSPHAMIDE'? | Using 18F-FDG PET/CT to rule out Richter transformation as cause of deterioration in a patient with chronic lymphatic leukemia and severe COVID-19: A case report.
BACKGROUND
This case report demonstrates the use of flourine-18 fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) to r... | 2 COURSES | DrugDosageText | CC BY | 34871217 | 20,547,124 | 2021-11-05 |
What was the dosage of drug 'FLUDARABINE PHOSPHATE'? | Using 18F-FDG PET/CT to rule out Richter transformation as cause of deterioration in a patient with chronic lymphatic leukemia and severe COVID-19: A case report.
BACKGROUND
This case report demonstrates the use of flourine-18 fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) to r... | 2 COURSES | DrugDosageText | CC BY | 34871217 | 20,547,124 | 2021-11-05 |
What was the dosage of drug 'IBRUTINIB'? | Using 18F-FDG PET/CT to rule out Richter transformation as cause of deterioration in a patient with chronic lymphatic leukemia and severe COVID-19: A case report.
BACKGROUND
This case report demonstrates the use of flourine-18 fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) to r... | TREATMENT FOR 6MONTHS | DrugDosageText | CC BY | 34871217 | 20,547,124 | 2021-11-05 |
What was the dosage of drug 'IMMUNE GLOBULIN NOS'? | Using 18F-FDG PET/CT to rule out Richter transformation as cause of deterioration in a patient with chronic lymphatic leukemia and severe COVID-19: A case report.
BACKGROUND
This case report demonstrates the use of flourine-18 fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) to r... | 2 COURSES | DrugDosageText | CC BY | 34871217 | 20,547,124 | 2021-11-05 |
What was the dosage of drug 'RITUXIMAB'? | Using 18F-FDG PET/CT to rule out Richter transformation as cause of deterioration in a patient with chronic lymphatic leukemia and severe COVID-19: A case report.
BACKGROUND
This case report demonstrates the use of flourine-18 fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) to r... | 2 COURSES | DrugDosageText | CC BY | 34871217 | 20,547,124 | 2021-11-05 |
What was the outcome of reaction 'COVID-19 pneumonia'? | Using 18F-FDG PET/CT to rule out Richter transformation as cause of deterioration in a patient with chronic lymphatic leukemia and severe COVID-19: A case report.
BACKGROUND
This case report demonstrates the use of flourine-18 fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) to r... | Recovered | ReactionOutcome | CC BY | 34871217 | 20,547,124 | 2021-11-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective for unapproved indication'. | Successful management of severe allergic reactions to platelet transfusion with omalizumab: A case report.
BACKGROUND
An allergic transfusion reaction is a common side effect of transfusions of red blood cells. Using washed red blood cells is the most effective method for preventing such a reaction. However, the availa... | AZACITIDINE, CHLORPHENIRAMINE, METHYLPREDNISOLONE, OMALIZUMAB | DrugsGivenReaction | CC BY | 34871268 | 20,580,982 | 2021-11-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Successful management of severe allergic reactions to platelet transfusion with omalizumab: A case report.
BACKGROUND
An allergic transfusion reaction is a common side effect of transfusions of red blood cells. Using washed red blood cells is the most effective method for preventing such a reaction. However, the availa... | AZACITIDINE, CHLORPHENIRAMINE, METHYLPREDNISOLONE, OMALIZUMAB | DrugsGivenReaction | CC BY | 34871268 | 20,580,982 | 2021-11-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Successful management of severe allergic reactions to platelet transfusion with omalizumab: A case report.
BACKGROUND
An allergic transfusion reaction is a common side effect of transfusions of red blood cells. Using washed red blood cells is the most effective method for preventing such a reaction. However, the availa... | AZACITIDINE, CHLORPHENIRAMINE, METHYLPREDNISOLONE, OMALIZUMAB | DrugsGivenReaction | CC BY | 34871268 | 20,580,982 | 2021-11-05 |
What is the weight of the patient? | Successful management of severe allergic reactions to platelet transfusion with omalizumab: A case report.
BACKGROUND
An allergic transfusion reaction is a common side effect of transfusions of red blood cells. Using washed red blood cells is the most effective method for preventing such a reaction. However, the availa... | 61 kg. | Weight | CC BY | 34871268 | 20,580,982 | 2021-11-05 |
What was the administration route of drug 'CHLORPHENIRAMINE'? | Successful management of severe allergic reactions to platelet transfusion with omalizumab: A case report.
BACKGROUND
An allergic transfusion reaction is a common side effect of transfusions of red blood cells. Using washed red blood cells is the most effective method for preventing such a reaction. However, the availa... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 34871268 | 20,580,982 | 2021-11-05 |
What was the administration route of drug 'METHYLPREDNISOLONE'? | Successful management of severe allergic reactions to platelet transfusion with omalizumab: A case report.
BACKGROUND
An allergic transfusion reaction is a common side effect of transfusions of red blood cells. Using washed red blood cells is the most effective method for preventing such a reaction. However, the availa... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 34871268 | 20,580,982 | 2021-11-05 |
What was the dosage of drug 'AZACITIDINE'? | Successful management of severe allergic reactions to platelet transfusion with omalizumab: A case report.
BACKGROUND
An allergic transfusion reaction is a common side effect of transfusions of red blood cells. Using washed red blood cells is the most effective method for preventing such a reaction. However, the availa... | 75 MILLIGRAM/SQ. METER | DrugDosageText | CC BY | 34871268 | 20,580,982 | 2021-11-05 |
What was the dosage of drug 'CHLORPHENIRAMINE'? | Successful management of severe allergic reactions to platelet transfusion with omalizumab: A case report.
BACKGROUND
An allergic transfusion reaction is a common side effect of transfusions of red blood cells. Using washed red blood cells is the most effective method for preventing such a reaction. However, the availa... | 4 MG, 1 HOUR PRIOR TO TRANSFUSION | DrugDosageText | CC BY | 34871268 | 20,580,982 | 2021-11-05 |
What was the dosage of drug 'METHYLPREDNISOLONE'? | Successful management of severe allergic reactions to platelet transfusion with omalizumab: A case report.
BACKGROUND
An allergic transfusion reaction is a common side effect of transfusions of red blood cells. Using washed red blood cells is the most effective method for preventing such a reaction. However, the availa... | 40 MG, AT 1, 7 AND 13 HOURS PRIOR TO TRANSFUSION | DrugDosageText | CC BY | 34871268 | 20,580,982 | 2021-11-05 |
What was the dosage of drug 'OMALIZUMAB'? | Successful management of severe allergic reactions to platelet transfusion with omalizumab: A case report.
BACKGROUND
An allergic transfusion reaction is a common side effect of transfusions of red blood cells. Using washed red blood cells is the most effective method for preventing such a reaction. However, the availa... | 150 MG,1WEEK BEFORE THE PLATELET TRANSFUSION | DrugDosageText | CC BY | 34871268 | 20,580,982 | 2021-11-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Acquired gene mutation'. | Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis: A case report.
BACKGROUND
Leptomeningeal metastasis (LM) is a fatal complication of advanced non-small cell lung cancer (NSCLC) with a poor prognosis. Osimertinib is a promising option ... | OSIMERTINIB | DrugsGivenReaction | CC BY | 34871271 | 20,300,278 | 2021-11-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Asthenia'. | Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis: A case report.
BACKGROUND
Leptomeningeal metastasis (LM) is a fatal complication of advanced non-small cell lung cancer (NSCLC) with a poor prognosis. Osimertinib is a promising option ... | ERLOTINIB | DrugsGivenReaction | CC BY | 34871271 | 20,601,033 | 2021-11-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Decreased appetite'. | Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis: A case report.
BACKGROUND
Leptomeningeal metastasis (LM) is a fatal complication of advanced non-small cell lung cancer (NSCLC) with a poor prognosis. Osimertinib is a promising option ... | ERLOTINIB | DrugsGivenReaction | CC BY | 34871271 | 20,601,033 | 2021-11-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Disease progression'. | Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis: A case report.
BACKGROUND
Leptomeningeal metastasis (LM) is a fatal complication of advanced non-small cell lung cancer (NSCLC) with a poor prognosis. Osimertinib is a promising option ... | ERLOTINIB | DrugsGivenReaction | CC BY | 34871271 | 20,601,033 | 2021-11-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug resistance'. | Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis: A case report.
BACKGROUND
Leptomeningeal metastasis (LM) is a fatal complication of advanced non-small cell lung cancer (NSCLC) with a poor prognosis. Osimertinib is a promising option ... | OSIMERTINIB | DrugsGivenReaction | CC BY | 34871271 | 20,300,278 | 2021-11-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Malignant neoplasm progression'. | Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis: A case report.
BACKGROUND
Leptomeningeal metastasis (LM) is a fatal complication of advanced non-small cell lung cancer (NSCLC) with a poor prognosis. Osimertinib is a promising option ... | OSIMERTINIB | DrugsGivenReaction | CC BY | 34871271 | 20,300,278 | 2021-11-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Metastases to meninges'. | Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis: A case report.
BACKGROUND
Leptomeningeal metastasis (LM) is a fatal complication of advanced non-small cell lung cancer (NSCLC) with a poor prognosis. Osimertinib is a promising option ... | OSIMERTINIB | DrugsGivenReaction | CC BY | 34871271 | 20,300,278 | 2021-11-05 |
What was the administration route of drug 'OSIMERTINIB'? | Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis: A case report.
BACKGROUND
Leptomeningeal metastasis (LM) is a fatal complication of advanced non-small cell lung cancer (NSCLC) with a poor prognosis. Osimertinib is a promising option ... | Oral | DrugAdministrationRoute | CC BY | 34871271 | 20,300,278 | 2021-11-05 |
What was the dosage of drug 'OSIMERTINIB'? | Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis: A case report.
BACKGROUND
Leptomeningeal metastasis (LM) is a fatal complication of advanced non-small cell lung cancer (NSCLC) with a poor prognosis. Osimertinib is a promising option ... | 80 mg (milligrams). | DrugDosage | CC BY | 34871271 | 20,300,278 | 2021-11-05 |
What was the outcome of reaction 'Acquired gene mutation'? | Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis: A case report.
BACKGROUND
Leptomeningeal metastasis (LM) is a fatal complication of advanced non-small cell lung cancer (NSCLC) with a poor prognosis. Osimertinib is a promising option ... | Not recovered | ReactionOutcome | CC BY | 34871271 | 20,300,278 | 2021-11-05 |
What was the outcome of reaction 'Drug resistance'? | Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis: A case report.
BACKGROUND
Leptomeningeal metastasis (LM) is a fatal complication of advanced non-small cell lung cancer (NSCLC) with a poor prognosis. Osimertinib is a promising option ... | Not recovered | ReactionOutcome | CC BY | 34871271 | 20,300,278 | 2021-11-05 |
What was the outcome of reaction 'Malignant neoplasm progression'? | Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis: A case report.
BACKGROUND
Leptomeningeal metastasis (LM) is a fatal complication of advanced non-small cell lung cancer (NSCLC) with a poor prognosis. Osimertinib is a promising option ... | Not recovered | ReactionOutcome | CC BY | 34871271 | 20,300,278 | 2021-11-05 |
What was the outcome of reaction 'Metastases to meninges'? | Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis: A case report.
BACKGROUND
Leptomeningeal metastasis (LM) is a fatal complication of advanced non-small cell lung cancer (NSCLC) with a poor prognosis. Osimertinib is a promising option ... | Not recovered | ReactionOutcome | CC BY | 34871271 | 20,300,278 | 2021-11-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Disease recurrence'. | Chimeric antigen receptor T-cell therapy following autologous transplantation for secondary central nervous system lymphoma: A case report.
BACKGROUND
Chimeric antigen receptor (CAR) T-cell therapy is effective in treating relapsed and refractory B-cell non-Hodgkin lymphoma. However, because of the mortality risk assoc... | CYCLOPHOSPHAMIDE, CYTARABINE, DOXORUBICIN, METHOTREXATE, PREDNISONE, RITUXIMAB, VINCRISTINE | DrugsGivenReaction | CC BY | 34871273 | 20,667,670 | 2021-11-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Therapy partial responder'. | Chimeric antigen receptor T-cell therapy following autologous transplantation for secondary central nervous system lymphoma: A case report.
BACKGROUND
Chimeric antigen receptor (CAR) T-cell therapy is effective in treating relapsed and refractory B-cell non-Hodgkin lymphoma. However, because of the mortality risk assoc... | CYCLOPHOSPHAMIDE, CYTARABINE, DOXORUBICIN, METHOTREXATE, PREDNISONE, RITUXIMAB, VINCRISTINE | DrugsGivenReaction | CC BY | 34871273 | 20,667,670 | 2021-11-05 |
What was the administration route of drug 'PREDNISONE'? | Chimeric antigen receptor T-cell therapy following autologous transplantation for secondary central nervous system lymphoma: A case report.
BACKGROUND
Chimeric antigen receptor (CAR) T-cell therapy is effective in treating relapsed and refractory B-cell non-Hodgkin lymphoma. However, because of the mortality risk assoc... | Oral | DrugAdministrationRoute | CC BY | 34871273 | 20,667,670 | 2021-11-05 |
What was the dosage of drug 'CYCLOPHOSPHAMIDE'? | Chimeric antigen receptor T-cell therapy following autologous transplantation for secondary central nervous system lymphoma: A case report.
BACKGROUND
Chimeric antigen receptor (CAR) T-cell therapy is effective in treating relapsed and refractory B-cell non-Hodgkin lymphoma. However, because of the mortality risk assoc... | 6 CYCLES | DrugDosageText | CC BY | 34871273 | 20,667,670 | 2021-11-05 |
What was the dosage of drug 'CYTARABINE'? | Chimeric antigen receptor T-cell therapy following autologous transplantation for secondary central nervous system lymphoma: A case report.
BACKGROUND
Chimeric antigen receptor (CAR) T-cell therapy is effective in treating relapsed and refractory B-cell non-Hodgkin lymphoma. However, because of the mortality risk assoc... | 3 CYCLES | DrugDosageText | CC BY | 34871273 | 20,667,670 | 2021-11-05 |
What was the dosage of drug 'DOXORUBICIN'? | Chimeric antigen receptor T-cell therapy following autologous transplantation for secondary central nervous system lymphoma: A case report.
BACKGROUND
Chimeric antigen receptor (CAR) T-cell therapy is effective in treating relapsed and refractory B-cell non-Hodgkin lymphoma. However, because of the mortality risk assoc... | 6 CYCLES | DrugDosageText | CC BY | 34871273 | 20,667,670 | 2021-11-05 |
What was the dosage of drug 'PREDNISONE'? | Chimeric antigen receptor T-cell therapy following autologous transplantation for secondary central nervous system lymphoma: A case report.
BACKGROUND
Chimeric antigen receptor (CAR) T-cell therapy is effective in treating relapsed and refractory B-cell non-Hodgkin lymphoma. However, because of the mortality risk assoc... | 6 CYCLES | DrugDosageText | CC BY | 34871273 | 20,667,670 | 2021-11-05 |
What was the dosage of drug 'RITUXIMAB'? | Chimeric antigen receptor T-cell therapy following autologous transplantation for secondary central nervous system lymphoma: A case report.
BACKGROUND
Chimeric antigen receptor (CAR) T-cell therapy is effective in treating relapsed and refractory B-cell non-Hodgkin lymphoma. However, because of the mortality risk assoc... | 8 CYCLES | DrugDosageText | CC BY | 34871273 | 20,667,670 | 2021-11-05 |
What was the dosage of drug 'VINCRISTINE'? | Chimeric antigen receptor T-cell therapy following autologous transplantation for secondary central nervous system lymphoma: A case report.
BACKGROUND
Chimeric antigen receptor (CAR) T-cell therapy is effective in treating relapsed and refractory B-cell non-Hodgkin lymphoma. However, because of the mortality risk assoc... | 6 CYCLES | DrugDosageText | CC BY | 34871273 | 20,667,670 | 2021-11-05 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective for unapproved indication'. | Pleural effusion in Klippel-Trenaunay syndrome: an uncommon manifestation.
Klippel-Trenaunay syndrome is characterized by a combination of vascular abnormalities and limb hypertrophy. Pleural effusion as a manifestation of this syndrome is almost never mentioned in the literature. We present a case of persistent bilate... | DOXYCYCLINE | DrugsGivenReaction | CC BY-NC | 34871406 | 20,882,248 | 2021-12-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Pleural effusion in Klippel-Trenaunay syndrome: an uncommon manifestation.
Klippel-Trenaunay syndrome is characterized by a combination of vascular abnormalities and limb hypertrophy. Pleural effusion as a manifestation of this syndrome is almost never mentioned in the literature. We present a case of persistent bilate... | DOXYCYCLINE | DrugsGivenReaction | CC BY-NC | 34871406 | 20,882,248 | 2021-12-06 |
What was the dosage of drug 'DOXYCYCLINE'? | Pleural effusion in Klippel-Trenaunay syndrome: an uncommon manifestation.
Klippel-Trenaunay syndrome is characterized by a combination of vascular abnormalities and limb hypertrophy. Pleural effusion as a manifestation of this syndrome is almost never mentioned in the literature. We present a case of persistent bilate... | UNK, CHEMICAL PLEURODESIS | DrugDosageText | CC BY-NC | 34871406 | 20,882,248 | 2021-12-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Condition aggravated'. | Methotrexate-induced toxidermia and pancytopenia in a patient with ectopic pregnancy: a case report.
BACKGROUND
Methotrexate is an anticancer drug from the antimetabolite class. It is also used in gynecology and obstetrics and is the molecule of choice for the medical treatment of ectopic pregnancies. We report a case ... | AMPHOTERICIN B, DEXAMETHASONE, ERYTHROMYCIN, FUSIDIC ACID, LORATADINE, OMEPRAZOLE, UNSPECIFIED INGREDIENT | DrugsGivenReaction | CC BY | 34872594 | 20,319,590 | 2021-12-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug eruption'. | Methotrexate-induced toxidermia and pancytopenia in a patient with ectopic pregnancy: a case report.
BACKGROUND
Methotrexate is an anticancer drug from the antimetabolite class. It is also used in gynecology and obstetrics and is the molecule of choice for the medical treatment of ectopic pregnancies. We report a case ... | METHOTREXATE | DrugsGivenReaction | CC BY | 34872594 | 20,211,160 | 2021-12-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hepatic cytolysis'. | Methotrexate-induced toxidermia and pancytopenia in a patient with ectopic pregnancy: a case report.
BACKGROUND
Methotrexate is an anticancer drug from the antimetabolite class. It is also used in gynecology and obstetrics and is the molecule of choice for the medical treatment of ectopic pregnancies. We report a case ... | METHOTREXATE | DrugsGivenReaction | CC BY | 34872594 | 20,197,992 | 2021-12-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Multiple organ dysfunction syndrome'. | Methotrexate-induced toxidermia and pancytopenia in a patient with ectopic pregnancy: a case report.
BACKGROUND
Methotrexate is an anticancer drug from the antimetabolite class. It is also used in gynecology and obstetrics and is the molecule of choice for the medical treatment of ectopic pregnancies. We report a case ... | METHOTREXATE | DrugsGivenReaction | CC BY | 34872594 | 20,232,797 | 2021-12-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pancytopenia'. | Methotrexate-induced toxidermia and pancytopenia in a patient with ectopic pregnancy: a case report.
BACKGROUND
Methotrexate is an anticancer drug from the antimetabolite class. It is also used in gynecology and obstetrics and is the molecule of choice for the medical treatment of ectopic pregnancies. We report a case ... | METHOTREXATE | DrugsGivenReaction | CC BY | 34872594 | 20,232,797 | 2021-12-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pneumonia'. | Methotrexate-induced toxidermia and pancytopenia in a patient with ectopic pregnancy: a case report.
BACKGROUND
Methotrexate is an anticancer drug from the antimetabolite class. It is also used in gynecology and obstetrics and is the molecule of choice for the medical treatment of ectopic pregnancies. We report a case ... | METHOTREXATE | DrugsGivenReaction | CC BY | 34872594 | 20,211,160 | 2021-12-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Renal failure'. | Methotrexate-induced toxidermia and pancytopenia in a patient with ectopic pregnancy: a case report.
BACKGROUND
Methotrexate is an anticancer drug from the antimetabolite class. It is also used in gynecology and obstetrics and is the molecule of choice for the medical treatment of ectopic pregnancies. We report a case ... | METHOTREXATE | DrugsGivenReaction | CC BY | 34872594 | 20,197,992 | 2021-12-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Septic shock'. | Methotrexate-induced toxidermia and pancytopenia in a patient with ectopic pregnancy: a case report.
BACKGROUND
Methotrexate is an anticancer drug from the antimetabolite class. It is also used in gynecology and obstetrics and is the molecule of choice for the medical treatment of ectopic pregnancies. We report a case ... | METHOTREXATE | DrugsGivenReaction | CC BY | 34872594 | 20,211,160 | 2021-12-07 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Toxic skin eruption'. | Methotrexate-induced toxidermia and pancytopenia in a patient with ectopic pregnancy: a case report.
BACKGROUND
Methotrexate is an anticancer drug from the antimetabolite class. It is also used in gynecology and obstetrics and is the molecule of choice for the medical treatment of ectopic pregnancies. We report a case ... | METHOTREXATE | DrugsGivenReaction | CC BY | 34872594 | 20,232,797 | 2021-12-07 |
What was the administration route of drug 'AMPHOTERICIN B'? | Methotrexate-induced toxidermia and pancytopenia in a patient with ectopic pregnancy: a case report.
BACKGROUND
Methotrexate is an anticancer drug from the antimetabolite class. It is also used in gynecology and obstetrics and is the molecule of choice for the medical treatment of ectopic pregnancies. We report a case ... | Oral | DrugAdministrationRoute | CC BY | 34872594 | 20,319,590 | 2021-12-07 |
What was the administration route of drug 'DEXAMETHASONE'? | Methotrexate-induced toxidermia and pancytopenia in a patient with ectopic pregnancy: a case report.
BACKGROUND
Methotrexate is an anticancer drug from the antimetabolite class. It is also used in gynecology and obstetrics and is the molecule of choice for the medical treatment of ectopic pregnancies. We report a case ... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 34872594 | 20,319,590 | 2021-12-07 |
What was the administration route of drug 'ERYTHROMYCIN'? | Methotrexate-induced toxidermia and pancytopenia in a patient with ectopic pregnancy: a case report.
BACKGROUND
Methotrexate is an anticancer drug from the antimetabolite class. It is also used in gynecology and obstetrics and is the molecule of choice for the medical treatment of ectopic pregnancies. We report a case ... | Oral | DrugAdministrationRoute | CC BY | 34872594 | 20,319,590 | 2021-12-07 |
What was the administration route of drug 'FUSIDIC ACID'? | Methotrexate-induced toxidermia and pancytopenia in a patient with ectopic pregnancy: a case report.
BACKGROUND
Methotrexate is an anticancer drug from the antimetabolite class. It is also used in gynecology and obstetrics and is the molecule of choice for the medical treatment of ectopic pregnancies. We report a case ... | Cutaneous | DrugAdministrationRoute | CC BY | 34872594 | 20,319,590 | 2021-12-07 |
What was the administration route of drug 'LORATADINE'? | Methotrexate-induced toxidermia and pancytopenia in a patient with ectopic pregnancy: a case report.
BACKGROUND
Methotrexate is an anticancer drug from the antimetabolite class. It is also used in gynecology and obstetrics and is the molecule of choice for the medical treatment of ectopic pregnancies. We report a case ... | Oral | DrugAdministrationRoute | CC BY | 34872594 | 20,319,590 | 2021-12-07 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.